$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
What should I do if I miss a dose of osimertinib? Will long-term treatment with osimertinib lead to drug resistance
2025-10-19 11:44:20
Check Details
Summary of the specific efficacy of entrectinib in treating different diseases
2025-10-19 11:44:20
Check Details
The clinical data of cabozantinib is impressive, and cabozantinib is cheaper to buy through this channel!
2025-10-19 11:44:20
Check Details
Is afatinib effective in treating lung cancer? How long does it usually take to get results
2025-10-19 11:44:20
Check Details
How should Erlotinib and Tarceva be used to treat lung cancer? What are the precautions
2025-10-19 11:44:20
Check Details
The efficacy of gefitinib has been confirmed and has been included in domestic medical insurance
2025-10-19 11:44:20
Check Details
Erlotinib prolongs patient survival by up to 11 months!
2025-10-19 11:44:20
Check Details
The third generation of EGFR-targeted drugs, a detailed explanation of osimertinib in one article
2025-10-19 11:44:20
Check Details
Compared with previous generation drugs, dacomitinib extends the survival period by more than half!
2025-10-19 11:44:20
Check Details
Compared with the previous generation of drugs, afatinib has more significant efficacy_ Kanghule
2025-10-19 11:44:20
Check Details
Tepotinib is approved for marketing in China, which is of great significance
2025-10-19 11:44:20
Check Details
How to solve the problem of hyperlipidemia in patients taking lorlatinib?
2025-10-19 11:44:20
Check Details
1
2
...
3982
3983
3984
3985
3986
3987
3988
...
4156
4157
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Global Update 2026: Selumetinib (KOSELUGO) Expands Indication to Adult NF1-PN and Clinical Management Strategies
2
Lenvatinib Safety Guide: Baseline Assessment & Adverse Reaction Management
3
Inluriyo (Imlunestrant): Oral SERD for ER+/HER2- Breast Cancer with ESR1 Mutations
4
Idelalisib: Oral PI3Kδ Inhibitor for Relapsed/Refractory Hematologic Malignancies
5
Lorlatinib (Lorviqua): Oral Targeted Therapy for ALK-Positive Advanced Non-Small Cell Lung Cancer
6
FDA Approves Ibrance for New Maintenance Indication in HR+/HER2+ Breast Cancer
7
FDA Approves Trodelvy for Two First-Line Indications, Redefining Advanced Triple-Negative Breast Cancer Care
8
Cabozantinib: A Pan-Targeted TKI in Modern Oncology Practice
9
Managing Amivantamab Infusion Reactions: A Clinical Guide for International Practice
10
Onset Timeline and Efficacy Assessment of Margetuximab plus Chemotherapy in HER2-Positive Metastatic Breast Cancer
11
Avutometinib Plus Defactinib: A Precision Therapy for KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer
12
Vemurafenib (Zelboraf) Complete Medication Guide